Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor 1 A-type (NFIA)
- Target
- NFIA
- Molecular classification
- Transcription factor, DNA-binding protein
01
Overview
Nuclear factor 1 A-type (NFIA) is a DNA-binding transcription factor encoded by the NFIA gene in humans. NFIA belongs to the Nuclear factor I family, which regulates gene expression by binding to specific DNA sequences as dimers. It plays a central role in the development of the central nervous system, particularly in initiating glial cell differentiation, and is implicated in both developmental processes (such as promoting the differentiation of neural stem cells into astrocytes and other glia) and adult tissue maintenance. NFIA is abnormally regulated in various cancers, including gliomas, hepatocellular carcinoma, and esophageal carcinoma, where it can either promote tumor progression or act as a tumor suppressor, depending on context. Additionally, it plays a role in CNS injury by regulating astrocyte responses and may be a marker for CNS tumor grading and disease progression.
- Other names
- NFIACTFNF-I/ANF1-ANFI-ANFI-L
02
Mechanism of action
Not applicable. No therapeutic agents directly modulate NFIA; however, experimental modulation could impact downstream gene expression, cell differentiation, and proliferation.
03
Biological functions
Regulation of gene expression (via DNA binding as a transcription factor)Promotion of astrocyte differentiation and specification of glial cell identity (especially in CNS development)Regulator of stem cell fate and differentiationModulation of responses to environmental signals and extracellular matrixRegulation of cellular differentiation and maintenance of adult stem cell populationsInvolvement in the central nervous system injury response and reactive astrogliosisRegulation of genes such as thrombospondin 4 in response to injury
04
Disease associations
Cancer, including glioma, hepatocellular carcinoma, esophageal squamous cell carcinoma, and uroepithelial bladder cancer (as both oncogenic and tumor suppressor roles depending on context)Neurodevelopmental disorders (defects in brain and lung maturation, skeletomuscular and renal abnormalities linked to NFIA mutations)Neurological disease (including white matter injury, glioma, astrocytoma, and response to CNS injury)Potential roles in inflammation and immune regulation
05
Safety considerations
There are no safety concerns documented specifically for targeting NFIA, but transcription factors are generally challenging drug targets due to their essential roles in multiple biological pathways and potential for off-target effects.
06
Biomarkers
NFIA expression is suggested as a biomarker in certain cancers (e.g., astrocytoma grade and prognosis)Evaluated as a marker of reactive astrocyte response in CNS injury
Beyond the preview
Go deeper on Nuclear factor 1 A-type (NFIA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear factor 1 A-type (NFIA).